Novelwise pharmaceutical corporation 2024-07-19T18:05:02+00:00

About Us


Novelwise Pharmaceutical Corporation was formerly the new drug research and development department of NatureWise Biotech & Medicals Corporation. As our new drug development projects reached significant milestones, the R&D department was established as a separate entity in 2023 to expedite its progress. For years, our commitment has been to pioneer innovative medicines through rigorous independent research and strategic partnerships, addressing unmet medical needs. Embracing a new era, Novelwise isdedicated to enhancing corporate competitiveness by developing innovative treatments for disease eradication. Headquartered in Taiwan, we have a global outlook.

Business Strategy

Leveraging our robust research capabilities, we engage in actively collaborate with the academic community to explore niche markets and identify promising target products. Through a thorough assessment of market dynamics, regulations frameworks, and scientific advancements, formulate optimal development strategies for drug candidates aimed at addressing diseases in need of enhanced treatment modalities. Our goal is to tackle unmet medical needs by spearheading the development of innovative drugs and offering solutions that prioritize efficacy, safety, and patient convenience.

R & D


NBM-BMX Capsule

NBM-BMX is a novel chemical compound designed to specifically inhibits the HDAC 8 protein. The developing isoform-selective HDAC inhibitors has become crucial due to the observed side effects limiting the clinical application of FDA-approved non-selective HDAC inhibitors. NBM-BMX demonstrates exceptional tumor inhibitory activity across various cancer types, particularly those exhibiting high expression levels of HDAC8 protein. Novelwise holds global rights to NBM-BMX, including manufacturing and sales. The phaseIb/II clinical trial for newly diagnosed GBM is ongoing.


NBM-BMX received USFDA approval to proceed Phase Ib/II clinical trial in newly diagnosed glioblastoma multiforme (GBM).

NatureWise’s new drug, NBM-BMX, received USFDA approval on January 4th, 2023 to proceed in Phase Ib/II clinical trials in newly diagnosed GBM. Glioblastoma multiforme is one of the most aggressive, invasive, and deadly malignancies. More than 60% of newly diagnosed GBM patients do not respond to standard treatment. Our studies demonstrated that NBM-BMX is a new therapeutic approach with the potential for addressing this need for safer, more effective treatment options for GBM.

2023 / 05 / 22|Categories: News|

The USFDA has reviewed and commented on the results of the phase 1 clinical trial of NBM-BMX and suggested changes on the draft clinical protocol of the phase 2 program

In 2018, in a letter approving the initiation of phase 1 clinical trials, the USFDA requested NatureWise schedule an end of phase 1 (EOP1) meeting with the FDA when NatureWise completed the phase 1 clinical program. In September 2021, NatureWise completed a phase 1 clinical trial in the USA, submitted the trial results to the USFDA along with a draft of the phase 2 [...]

2022 / 01 / 06|Categories: News|
error: Content is protected !!